Attached files
file | filename |
---|---|
EX-10.1 - AGREEMENT - VITRO DIAGNOSTICS INC | vds_ex10z1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 21, 2015
VITRO DIAGNOSTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Nevada | 0-17378 | 84-1012042 |
(State or other jurisdiction | Commission File | (I.R.S. Employer Identification number) |
4621 Technology Drive, Golden CO 80403
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (303) 999-2130
______________________________________________________
(Former name or former address, if changed since last report)
___ | Written communications pursuant to Rule 425 under the Securities Act |
___ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act |
___ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act |
___ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act |
ITEM 3.02 | UNREGISTERED SALE OF EQUITY SECURITIES |
|
|
ITEM 8.01 | OTHER EVENTS |
On August 21, 2015, Vitro Diagnostics, Inc. (the Company) entered into an agreement (the Agreement) with C. Brook Ventures, Inc. (CBV) pursuant to which CBV will provide non-exclusive advisory services related to the Companys exploration of strategic alternatives to enhance stockholder value.
Under the terms of the Agreement, the Company agreed to pay CBV a retainer of $5,000 and issue to CBV an aggregate of 400,000 shares of common stock, $.001 par value. The shares are restricted securities under the Securities Act of 1933, as amended.
In addition, the Agreement provides that the Company will grant and issue to CBV a warrant (Warrant) exercisable for three years to purchase an additional 400,000 shares at an exercise price of $0.078936 (120% of the 20 day VWAP immediately preceding the execution of the Agreement.) The Warrant is only exercisable if the Company consummates a transaction identified in the Agreement with a third party introduced by CBV prior to the expiration date of the Warrant.
ITEM 9.01 | EXHIBITS |
10.1
Agreement with C. Brook Ventures, Inc. dated August 21, 2015
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
| Vitro Diagnostics, Inc. | |
|
|
|
|
| Dated: August 27, 2015 |
| __/s/James R. Musick James R. Musick, President and Chief Executive Officer |
|
|
|
|
2